Microbot Medical Expands Northeast Presence as Pennsylvania Health System Adopts LIBERTY® Endovascular Robotic Platform
Microbot Medical Inc., the medical technology company behind the innovative LIBERTY® Endovascular Robotic System, has announced another significant milestone in its commercialization journey. A globally recognized academic healthcare organization headquartered in Pennsylvania has become the first health system in the state to adopt the LIBERTY® platform, marking an important expansion of the company’s growing presence across the Northeastern United States.
The latest adoption represents more than just the addition of a new customer. It highlights the increasing momentum behind robotic-assisted endovascular procedures and reflects the growing confidence that healthcare providers are placing in technologies designed to improve precision, efficiency, and physician control during minimally invasive vascular interventions. With this new agreement, Microbot Medical continues to strengthen its position in key healthcare markets while laying the groundwork for broader national and international expansion.
Strengthening Presence in Strategic Healthcare Markets
The Pennsylvania-based academic health system joins a growing network of leading medical institutions that have adopted the LIBERTY® Endovascular Robotic System. The company has already established partnerships with health systems in major metropolitan areas such as New York City and Boston, two regions widely recognized for their concentration of advanced medical centers, research institutions, and innovation-driven healthcare organizations.
By adding a prominent Pennsylvania healthcare provider to its customer base, Microbot Medical expands its reach into another critical healthcare corridor in the northeastern United States. Pennsylvania and neighboring New Jersey collectively represent one of the country’s most densely populated and medically active regions, serving millions of patients through extensive hospital networks, specialty clinics, and academic medical centers.
The newly signed customer operates multiple hospitals and multispecialty medical facilities throughout Pennsylvania and New Jersey. This broad geographic footprint offers significant opportunities for the integration of robotic-assisted vascular procedures across various clinical environments and patient populations.
Notably, this healthcare organization becomes the second customer in Microbot Medical’s portfolio whose network spans multiple states. The company’s New York City-based customer similarly operates healthcare facilities in New Jersey, illustrating a growing trend among large health systems to adopt innovative technologies across expansive regional networks.
Growing Adoption Across Multiple States
The Pennsylvania agreement contributes to a broader pattern of adoption that is helping establish Microbot Medical’s national footprint. The company now reports active accounts across seven states in the eastern United States, with multiple hospitals throughout these healthcare systems utilizing or preparing to implement the LIBERTY® platform.
This expanding customer base reflects the company’s focused commercialization strategy and demonstrates increasing market acceptance of robotic-assisted endovascular technologies. Healthcare organizations are continually evaluating solutions that can improve procedural outcomes while addressing operational challenges such as physician workload, workflow efficiency, and procedural consistency.
The adoption of robotic systems in vascular interventions has become an area of increasing interest as hospitals seek technologies capable of supporting complex procedures while enhancing physician capabilities. As more institutions gain experience with robotic-assisted platforms, industry observers expect adoption rates to continue rising across both academic and community healthcare settings.
For Microbot Medical, the growing number of installations provides valuable validation of its technology while creating opportunities to demonstrate clinical utility in diverse healthcare environments.
The Evolution of Endovascular Robotics
Endovascular procedures have transformed modern medicine by enabling physicians to treat vascular conditions through minimally invasive techniques rather than traditional open surgery. These procedures typically involve navigating catheters, guidewires, and other devices through blood vessels to diagnose or treat cardiovascular, peripheral vascular, neurovascular, and other conditions.
Despite the advantages of minimally invasive interventions, endovascular procedures can present significant technical challenges. Physicians must navigate intricate vascular pathways while maintaining precise control over instruments, often while being exposed to radiation and wearing heavy protective equipment for extended periods.
Robotic-assisted systems have emerged as a promising solution to address these challenges. By providing enhanced instrument control and allowing physicians to operate from a more comfortable and potentially less radiation-exposed environment, robotic technologies aim to improve both procedural performance and physician experience.
The LIBERTY® Endovascular Robotic System was developed specifically to address these needs. Designed as a compact and advanced robotic platform, the system enables physicians to remotely control endovascular devices during procedures while maintaining high levels of precision and responsiveness.
As healthcare organizations increasingly explore ways to integrate robotics into various specialties, endovascular robotics represents one of the most promising areas for technological advancement within minimally invasive medicine.
Commercialization Momentum Following Full Market Release
Microbot Medical’s latest customer announcement comes shortly after the company entered a new phase of commercialization with the full market release of the LIBERTY® system during the second quarter of the year.
The transition from limited commercialization activities to broader market availability marks a critical stage in the life cycle of any medical technology company. Full market release allows organizations to expand sales activities, engage a larger number of healthcare providers, and accelerate adoption across multiple geographic regions.
For Microbot Medical, the timing of the Pennsylvania adoption underscores the effectiveness of this transition. The company is beginning to see increased interest from healthcare organizations across its existing sales territories while simultaneously preparing to enter new markets.
The successful onboarding of major health systems in key metropolitan regions provides a strong foundation for future growth. Academic medical centers often serve as important reference sites for emerging technologies because they frequently influence adoption trends throughout the broader healthcare community.
As more physicians gain experience with robotic-assisted endovascular procedures, positive outcomes and operational benefits may encourage additional hospitals and healthcare systems to explore similar investments.
Expansion Plans Beyond the Eastern United States
Building on its growing momentum in the Northeast, Microbot Medical is now preparing to extend its commercial reach beyond its current territories.
The company has announced plans to expand its sales footprint into the Western United States, a move that could significantly increase access to the LIBERTY® platform among healthcare providers across the country.
The West Coast represents an attractive market for advanced medical technologies due to its concentration of leading academic institutions, major healthcare systems, and innovation-focused medical communities. States such as California, Washington, and Oregon are home to numerous hospitals known for adopting cutting-edge technologies and participating in clinical innovation initiatives.
By entering western markets, Microbot Medical aims to broaden awareness of the LIBERTY® system while creating new opportunities for customer acquisition and long-term revenue growth.
Expansion into new territories also provides opportunities to diversify the company’s customer base and reduce reliance on any single geographic market. As healthcare technology adoption continues to evolve, broader national coverage may become increasingly important for supporting sustainable growth.
Supporting Federal Healthcare Systems
In addition to expanding within traditional healthcare markets, Microbot Medical recently announced an agreement designed to broaden access to the LIBERTY® platform within certain federal healthcare systems across the United States.
These healthcare networks include facilities that serve veterans, active-duty military personnel, and other eligible patient populations. Such organizations represent an important segment of the healthcare landscape, often managing large patient volumes and complex clinical needs.
The agreement has the potential to introduce robotic-assisted endovascular technologies to a wider range of healthcare providers and patients. Federal healthcare systems frequently evaluate technologies that can improve clinical outcomes, enhance operational efficiency, and support long-term care objectives.
By securing opportunities within these networks, Microbot Medical is positioning itself to reach additional physicians and healthcare facilities while reinforcing confidence in the broader adoption potential of its technology.
The company views this development as an important component of its growth strategy and believes it may help accelerate implementation efforts across both existing and future customer accounts.
Leadership Expresses Confidence in Adoption Strategy
Commenting on the latest customer acquisition, company leadership emphasized the significance of continued adoption among highly respected healthcare institutions.
According to Microbot Medical leadership, securing partnerships with prestigious health systems validates the company’s commercialization strategy and demonstrates growing confidence in the LIBERTY® platform. The ability to attract leading academic and regional healthcare organizations is viewed as a strong indicator of market interest and long-term opportunity.
Company executives also highlighted the positive response being observed across newly established sales territories following the full market release. Interest from healthcare providers in multiple regions supports the company’s plans to continue expanding its commercial infrastructure while investing in future growth initiatives.
Leadership believes that growing demand from hospitals and physicians, combined with increasing awareness of robotic-assisted endovascular procedures, creates a favorable environment for continued market penetration.
International Opportunities on the Horizon
While much of the company’s current focus remains centered on the United States, Microbot Medical is also laying the groundwork for future international expansion.
Healthcare systems around the world are increasingly investing in advanced robotic technologies to improve patient care and support physician performance. As robotic-assisted interventions become more widely accepted across multiple specialties, demand for innovative endovascular solutions is expected to grow internationally.
Establishing infrastructure in global markets requires careful planning, including regulatory approvals, distribution partnerships, physician training programs, and localized support capabilities. Microbot Medical has indicated that it is actively working to build these foundations while continuing to strengthen its domestic presence.
International expansion could eventually provide access to substantial new markets and further position the LIBERTY® system as a globally recognized platform within the field of robotic endovascular intervention.
The adoption of the LIBERTY® Endovascular Robotic System by a leading Pennsylvania academic health system represents another important step in Microbot Medical’s commercialization journey. With customers now spanning seven states across the eastern United States and additional expansion planned for western markets, the company is steadily building a nationwide presence.
The announcement reflects growing interest in robotic-assisted vascular procedures and underscores the healthcare industry’s ongoing commitment to technologies that enhance precision, efficiency, and clinical performance. Combined with new opportunities within federal healthcare systems and continued international development efforts, the Pennsylvania adoption strengthens the company’s outlook for future growth.
As hospitals and physicians continue exploring innovative approaches to minimally invasive care, Microbot Medical appears well-positioned to capitalize on the increasing demand for advanced robotic solutions in endovascular medicine. The company’s expanding customer network, strategic market expansion initiatives, and commitment to technological innovation suggest that the LIBERTY® platform may play an increasingly important role in the future of vascular intervention.
Source link: https://ir.microbotmedical.com/
